



Patent
Atty. Dkt. No. 084335-0143

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KITAMURA, et al.
Title: NOVEL CYTOKINE RECEPTOR-LIKE PROTEIN
Appl. No.: 09/913,728
Filing Date: October 23, 2001
Examiner: Regina Deberry
Art Unit: 1647

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56 AND § 1.97**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on a modified Form SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. Copies of the listed documents are being submitted to comply with the provisions of 37 CFR §1.97-1.98.

The submission of such a document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

TIMING OF THE DISCLOSURE AND FEE

The instant Information Disclosure Statement is being filed after a final Office Action has been mailed out by the PTO under 37 CFR §1.113. Accordingly, pursuant to 37 CFR

§1.97(d), a statement and fee are required. The statement under 37 CFR § 1.97(e)(2) is listed below and the fee under 37 CFR § 1.17(p) is enclosed.

STATEMENT

The undersigned hereby states in accordance with 37 C.F.R. § 1.97(e)(1) that no item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this Information Disclosure Statement.

CONCISE EXPLANATION OF RELEVANCE

Documents A1-A3 were discovered during a routing search by the client. Documents A1-A3 are in English.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of Form SB/08 be returned in accordance with MPEP §609.

Respectfully submitted,

Date June 23, 2004

By 


FOLEY & LARDNER LLP
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35, 264

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>June 23, 2004</u> (use as many sheets as necessary)		Complete if Known	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	09/913,728 10/23/2001 Toshio KITAMURA et al 1647 R. DeBerry 084335-0143
Sheet	1	of	1



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A1	LUO, Hong, et al., "An amino acid substitution in the <i>Drosophila hop</i> ^{1um-1} Jak kinase causes leukemia-like hematopoietic defects", <u>The EMBO Journal</u> , vol. 14, no. 7, pp 1412-1420, Oxford University Press, 1995	
	A2	LACRONIQUE, Virginie, et al., "A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia", <u>Science</u> , vol. 278, Nov. 14, 1997, pp 1309-1312	
	A3	MEYDAN, Naftaly, et al., "Inhibition of acute lymphoblastic leukaemia by a JAK-2 inhibitor", <u>Nature</u> , vol. 379, Feb. 15, 1996, pp 645-648	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

002.1215153.1